2010 Scientific Meeting Focuses on Growing Public Health Problem: Heart Valve Diseases

The Second Annual Joint Scientific Meeting of the Heart Valve Society of America & Society for Heart Valve Disease will be held in New York City from April 15 - 17. Valves in the Heart of the Big Apple VI: Evaluation & Management of Valvular Heart will provide state-of-the-art information about the latest strategies for diagnosis and treatment of this growing public health problem. Submissions are open for cases and abstracts for presentation during the session.

(PRWEB) November 23, 2009 -- Heart valve disease will be the focus of the Second Annual Joint Scientific Meeting of the world’s most prominent heart valve disease societies — the Heart Valve Society of America (HVSA) and Society for Heart Valve Disease (SHVD). The conference — Valves in the Heart of the Big Apple VI: Evaluation & Management of Valvular Heart Diseases 2010 will take place April 15-17, 2010 in New York City.

In addition to a series of state-of-the-art plenary lectures and mini-symposia, the conference is inviting physicians from around the world to submit their most challenging valvular heart disease case for the consideration for presentation during the event.

Case categories include:

* Aortic stenosis
* Aortic regurgitation
* Mitral stenosis
* Mitral regurgitation
* Endocarditis
* Valve disease & atrial fibrillation
* Valve disease & aortic aneurysm
* Valve disease & CAD

In addition, the conference will provide the opportunity for authors to compete to present original research in oral or poster format.

Abstract categories include:

* Cell and molecular biology of valve and/or myocardial dysfunction in valve disease
* Objective evaluation of hemodynamic severity
* Epidemiology/Prognostication
* Surgical therapy — methods
* Surgical therapy — results
* Catheter-based therapy techniques and results
* Medical therapy
* Arrhythmias associated with valve diseases
* New valve prostheses
Cases and abstracts can be submitted through December 22, 2010.

In addition to HVSA and SHVD, the conference is co-sponsored by the New York Cardiological Society of the New York State Chapter/American College of Cardiology.

Valves in the Heart of the Big Apple VI: Evaluation & Management of Valvular Heart Disease 2010 has been approved for AMA PRA Category 1 Credit. CME credits will be provided by SUNY Downstate Medical Center, Office of Continuing Medical Education.

Valvular heart diseases are among the most prominent causes of heart failure and premature cardiac death. It is estimated that more than 15 million Americans have some type of heart valve abnormality, and in more than five million, the disease is moderate to severe. Three to four million will require surgery at some time in their lives.

Valve diseases increase in frequency as people grow older. With the aging of the Baby Boom generation, heart valve diseases are emerging as an important public health concern.

Valves in the Heart of the Big Apple VI: Evaluation and Management of Valvular Heart Diseases 2010 will provide state-of-the-art information for cardiologists, cardiothoracic surgeons, other physicians, researchers, allied health professionals, fellows and students from around the world.

The symposium will be conducted by nationally and internationally-recognized clinicians and researchers specializing in the field.

Course features include:

* Current criteria for surgical intervention
* Cell and molecular biology of valve and/or myocardial dysfunction in valve disease
* Generally-accepted and recently-emerging predictors of prognostically- important deterioration among common lesions
* Current approaches to preparation of the patient with valve disease for anesthesia
* Emerging data on the use of percutaneous techniques for valve repair and replacement
* Regulatory concerns related to development of percutaneous valves
* Basis for operation in patients with multivalve disease
* Current data on selection among bioprosthetic valves and between mechanical and bioprosthetic valves
* The controversial role of drug prophylaxis for asymptomatic patients
* Predictive value of ventricular arrhythmias in patients with valve disease
* Current perspective on aortic valve repair for aortic valve diseases in association with aortic aneurysm — long-term followup and new approaches to selection of candidates
* Relative efficacy of medical and surgical therapies for mitral regurgitation secondary to cardiomyopathy
* Impact of age on morbidity and mortality in valve surgery — an update
* Anti-coagulation strategy in valve disease and after valve replacement
* Criteria for mitral valve surgery when mitral regurgitation is secondary to ischemic injury

The program executive committee comprises:

Jeffrey S. Borer, M.D. (co-chair)

If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears here - PRWeb ebooks - Another online visibility tool from PRWeb.
Professor and Chairman, Department of Medicine and Chief/Division of Cardiovascular Medicine
SUNY Downstate Medical Center
President, Heart Valve Society of America

Maurice E. Sarano, M.D. (co-chair)
Director, Valvular Heart Disease Clinic, Mayo Clinic
Executive Vice President, Heart Valve Society of America

Robert O. Bonow, MD
Goldberg Distinguished Professor of Medicine; Chief, Division of Cardiology, Northwestern University Medical School
President, Society of Heart Valve Disease; Vice President/Heart Valve Society of America

Friedrich W. Mohr, MD, PhD
Herzzentrum Universitaet Leipzig
Past President, Society of Heart Valve Disease

Cary W. Akins, MD
Clinical Professor of Surgery, Harvard Medical School; Division of Cardiac Surgery, Massachusetts General Hospital
Vice President/Heart Valve Society of America

O. Wayne Isom, MD
Terry Allen Kramer Professor and Chairman, Department of Cardiothoracic Surgery, Weill Medical College of Cornell University
Vice President, Heart Valve Society of America

The Heart Valve Society of America was founded to advance recognition and knowledge of the field. Its mission is to promote research, educate medical professionals about the evaluation and treatment of heart valve disease, serve as an informational resource for government, private industry, health care providers, the media and public, and encourage and facilitate education of future heart valve disease specialists.

The Society of Heart Valve Disease has as its objective to undertake, promote, support and encourage research and educate the public in the causes, prevention and treatment of heart valve disease. Its mission is to advance the practice, science and art of treating heart valve disease, through a multi-disciplinary approach with the ultimate aim of reducing the global burden of the disease.

###
Contact Information
LESLIE J. YERMAN
212-327-2107

Online Web 2.0 Version
You can read the online version of this press release here.